EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE 9600TFX23

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed with the FDA on 2019-05-23 for EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE 9600TFX23 manufactured by Edwards Lifesciences.

Event Text Entries

[146041268] (b)(4). Valve migration and regurgitation are potential risks associated with the use of the valve.? According to literature review, valve migration results when forces acting on the transcatheter heart valve (thv) overcome the strength of attachment of the valve to the landing zone. Less-than-severe and non-uniformly distributed calcification, incorrect valve sizing, and incomplete frame expansion, and can contribute to valve migration. Malposition is another risk factor for migration and regurgitation. If the valve is deployed too atrial, it may not cover the native mitral valve. As a result, the native mitral leaflet deflected flow, creating a venturi effect where a reduction in blood pressure resulting in mitral regurgitation. The edwards sapien 3 transcatheter heart valve is indicated for patients with symptomatic heart? Disease due to failure (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic or mitral valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (i. E. , society of thoracic surgeons operative risk score =8% or at a =15% risk of mortality at 30 days).? Deployment of the sapien 3 valve in a native mitral valve is not indicated per the labeling; therefore the labeling (ifus and ew training manuals) do not instruct the operator how to position the sapien 3 valve in this scenario.? The device remains implanted in the patient. In this case, the cause of the valve migration and subsequent mitral insufficiency noticed one month post deployment of the s3 valve in the native mitral annulus cannot be determined. However, there was no allegation or indication of a device malfunction. It is possible that some of the risk factors mentioned above caused or contributed to the event. Complaint histories for all reported events are reviewed against trending control limits on a monthly basis, and any excursions above the control limits are assessed and documented as part of this monthly review. No corrective or preventative actions are required.
Patient Sequence No: 1, Text Type: N, H10


[146041269] As reported, approximately 1 month post transcatheter mitral valve replacement (tmvr) with a 29mm s3 valve in the native mitral position via transseptal approach, the patient developed mitral insufficiency and a 2nd valve was implanted.? Per report, the physician believed the 1st valve migrated and left the patient with mitral insufficiency.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number2015691-2019-01850
MDR Report Key8638674
Date Received2019-05-23
Date of Report2019-05-02
Date of Event2019-05-02
Date Mfgr Received2019-05-02
Device Manufacturer Date2019-01-20
Date Added to Maude2019-05-23
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactMS. FRANCES PRESTON
Manufacturer Street1 EDWARDS WAY
Manufacturer CityIRVINE CA 92614
Manufacturer CountryUS
Manufacturer Postal92614
Manufacturer Phone9492505190
Manufacturer G1EDWARDS LIFESCIENCES LLC
Manufacturer Street1 EDWARDS WAY
Manufacturer CityIRVINE CA 92614
Manufacturer CountryUS
Manufacturer Postal Code92614
Single Use3
Remedial ActionOT
Previous Use Code3
Event Type3
Type of Report0

Device Details

Brand NameEDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE
Generic NamePROSTHESIS, MITRAL VALVE, PERCUTANEOUSLY DELIVERED
Product CodeNPU
Date Received2019-05-23
Model Number9600TFX23
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device Eval'ed by Mfgr*
Device Sequence No1
Device Event Key0
ManufacturerEDWARDS LIFESCIENCES
Manufacturer Address1 EDWARDS WAY IRVINE CA 92614 US 92614


Patients

Patient NumberTreatmentOutcomeDate
101. Required No Informationntervention 2019-05-23

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.